Immunotherapy Approaches on Innate Immunity for SARS-Cov2.

Immunotherapy Approaches on Innate Immunity for SARS-Cov2. Acta Virol. 2020 Sep 28;: Authors: Arslan BA, Timucin AC Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused fatal outbreaks of pneumonia. The similarity of S protein of SARS-CoV-2 with SARS-CoV and RaTG13 is about 76% and 97% respectively.  Also its potential receptor-binding domain (RBD) shows similarity with approximately 74% and 90.1% for SARS-CoV and RaTG13. SARS-CoV-2 has been shown to use the SARS-CoV receptor ACE2 for entry and serine protease TMPRSS2 for S protein. Sialic acids are primarily expressed by vertebrates and some microbial pathogens improving the ability to avoid from immune system of vertebrate host. Interactions of siglecs with their ligands play an important role in modulating immune cell functions activities as their regulators. Therefore, while Siglecs helps immune cells to distinguish between self and non-self, non-self ligands of some sialylated pathogens can recognize siglecs and reduce immune cell responses or escape from immune surveillance. In this review, innate immunity in SARS-CoV2 infection was discussed through Siglecs, especially Siglec-7, Siglec-3, NKG2A and neuraminidases. Keywords: SARS-Cov2; siglecs; NK cells; NKG2A; neuraminidases. PMID: 32985199 [PubMed - as supplied by publisher]
Source: Acta Virologica - Category: Infectious Diseases Authors: Tags: Acta Virol Source Type: research